Navigation Links
Lilly and International Council of Nurses Win Partnership Award From the U.S. Chamber of Commerce Business Civic Leadership Center
Date:11/19/2008

ffort involving nurses, doctors, hospital administrators, research institutions, businesses, governments, and social service and advocacy institutions," Lechleiter said. "Stopping MDR-TB is not about a single action -- it's about a series of joint initiatives that improve survival for some of the world's most vulnerable and hard-to-treat patients -- and give them hope."

David Benton, CEO of the International Council of Nurses, underscored the importance of the Partnership. "Nurses are the world's front-line resource against the deadly global pandemics facing us today. Lilly's support has helped us scale up our training efforts so we can save millions of lives by properly diagnosing and treating TB and MDR-TB."

The Clinton Global Initiative also recognized the Lilly/ICN partnership in September this year for its commitment to "implement innovative solutions designed to produce tangible results that will positively change lives."

About the International Council of Nurses (ICN)

The International Council of Nurses (ICN) is a federation of 132 national nurses associations representing the millions of nurses worldwide. Operated by nurses and leading nursing internationally, ICN works to ensure quality nursing care for all and sound health policies globally.

About The Lilly MDR-TB Partnership

The Lilly MDR-TB Partnership was created to confront multidrug-resistant tuberculosis (MDR-TB), a disease so daunting that no single organization can fight it alone. The public-private partnership mobilizes 18 partners on five continents in the battle to stop the spread of this disease and ultimately save lives. The Lilly MDR-TB Partnership is especially active in the high-burden countries of China, India, Russia and South Africa. Lilly's has financially invested $135 million for this effort. More information is available at www.lilly
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Lilly Announces Major Donation of Insulin to International Diabetes Federations Life for a Child Program; Initial Focus Will Be on Sub-Saharan Africa
2. American Diabetes Association and Eli Lilly and Company Unite to Educate and Empower African-Americans with Diabetes
3. Teach For America and Lilly Launch Program to Match Lilly Employees with Teachers in Underserved Public Schools
4. Lilly to Sponsor Congressional Black Caucus Foundations Annual Legislative Conference
5. Lilly Set to Become First Pharmaceutical Research Company to Disclose Physician Payments
6. Lilly and Amylin Set Date and Time for Conference Call
7. Covance and Lilly Enter Into a Strategic R&D Collaboration
8. Covance Recognized for Outstanding Customer Service by Eli Lilly and Company
9. Eli Lilly and Company and Vision Racing Sponsor Vision Wellness Tour at the IndyCar Series Across the Country
10. Lilly Partners With the National Council of La Raza to Fight Chronic Disease
11. Lilly Supports Industry Code on Interactions with Healthcare Professionals
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 2Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 3Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 4ARKRAY, Inc. Receives FDA 510k Clearance on the Assure(R) Platinum Auto-Code Blood Glucose Monitoring System 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4Service Corporation International Announces Schedule For Its Second Quarter 2009 Earnings Release and Conference Call 52397 1Service Corporation International Announces Schedule For Its Second Quarter 2009 Earnings Release and Conference Call 52397 2Biomodels Expands Efforts in Cancer Supportive Care Pulmonary Fibrosis 3B Preclinical Research Organization Names Dr Stephen T Sonis as Partner 13146 1Biomodels Expands Efforts in Cancer Supportive Care Pulmonary Fibrosis 3B Preclinical Research Organization Names Dr Stephen T Sonis as Partner 13146 2Is somatic hypersensitivity a predictor of irritable bowel syndrome 3F 52394 1Is somatic hypersensitivity a predictor of irritable bowel syndrome 3F 52394 2